GMR
The Original

UNRAVELLING THE MOLECULAR MECHANISMS OF *ABUTILON INDICUM* IN CERVICAL CANCER THROUGH NETWORK PHARMACOLOGY AND MOLECULAR DOCKING APPROACH

Aswathi K Biju[1], Malathi Vellaiperumal[2], K Hema Shree*[3], Parameswari R P[4]

[1] Department of Bioinformatics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai-602105, India. Email: aswathikb04@gmail.com, ORCID iD: 0009-0003-5426-3471
[2]Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai-602105, India. Email: malathiv84@gmail.com, ORCID iD: 0009-0008-1881-739X
[3]Department of Pathology, Saveetha Institute of Basic Medical Sciences, Saveetha Institute of Medical and Technical Sciences, Chennai-602105, India. Email: hemashree9111990@gmail.com, ORCID iD: 0000-0001-9616-6539
[4]Molecular Biochemistry Lab, Saveetha College of Physiotherapy, Saveetha Institute of Medical and Technical Sciences, Chennai-602105, India. Email: paramsarathy@gmail.com, ORCID iD: 0000-0003-3167-2873
*Corresponding Author: K Hema Shree, Email: hemashree9111990@gmail.com

ABSTRACT
Cervical cancer remains a leading cause of cancer-related morbidity and mortality among women globally, and the search for safer, multi-target therapeutic alternatives to conventional cytotoxic regimens continues to intensify. *Abutilon indicum*, a plant long used in Indian traditional medicine, has been credited with anti-inflammatory, antioxidant and antiproliferative properties, yet the molecular basis of its anticancer action against cervical cancer has not been systematically mapped. In the present study, an integrated network pharmacology and molecular docking workflow was used to identify the phytochemical-target-pathway architecture underlying the activity of *A. indicum* against cervical cancer. Thirty-seven phytochemicals were screened, yielding 404 predicted human protein targets, which were cross-referenced against 585 cervical cancer-associated genes to reveal 78 common targets. Protein-protein interaction network analysis and CytoHubba MCC ranking identified BCL2 as the topmost hub gene, and Gene Ontology/KEGG enrichment implicated pathways centred on apoptosis regulation and the EGFR tyrosine kinase inhibitor resistance cascade. Molecular docking of linoleic acid against the BCL2 crystal structure (PDB: 6O0K) revealed a stable binding pose (binding energy -4.29 kcal/mol) stabilised by hydrogen bonds with Arg66 and Tyr67 and hydrophobic contacts with Ala59, Phe63, Val107 and Tyr161. These findings provide a mechanistic, systems-level rationale for the traditional use of *A. indicum* and nominate the BCL2-linoleic acid interaction as a testable lead for future experimental validation in cervical cancer models.

KEYWORDS: *Abutilon indicum*, Cervical Cancer, network pharmacology, molecular docking, Healthy Lives, Well-being, Quality Care.

1. INTRODUCTION
Cervical cancer continues to impose a disproportionate burden on women's health worldwide, with the most recent Global Cancer Observatory (GLOBOCAN) estimates recording approximately 662,301 new cases and 348,874 deaths in 2022, figures that are projected to rise further as populations age and expand (1). Positioned among the four most frequently diagnosed cancers in women, cervical cancer disproportionately affects low- and middle-income regions where organised screening and human papillomavirus (HPV) vaccination coverage remain incomplete (2,3). Persistent infection with high-risk HPV genotypes is now firmly established as the principal aetiological driver of cervical carcinogenesis, acting through the sustained expression of viral oncoproteins that dismantle host tumour-suppressor checkpoints (4).
Despite decades of refinement in surgery, radiotherapy and platinum-based chemotherapy, outcomes for recurrent or metastatic disease have improved only marginally, and current guideline-directed second-line options such as checkpoint inhibitors and antiangiogenic combinations are costly, are not universally accessible, and are frequently accompanied by substantial toxicity (5). This therapeutic plateau has renewed interest in phytochemical agents as adjunct or alternative anticancer leads, particularly compounds capable of re-engaging apoptotic machinery that tumour cells have learned to evade (6). Unlike single-target cytotoxic drugs, plant-derived molecules typically act on several nodes of the disease-associated interactome simultaneously, a polypharmacological property that is difficult to capture through conventional reductionist pharmacology.
Network pharmacology has emerged as the methodological bridge that allows this multi-target behaviour to be modelled explicitly, replacing the historical "one drug-one target" paradigm with a systems-level view in which a phytochemical, its predicted protein targets, and a disease-gene set are analysed as a single interconnected network (7). Recent applications of this approach have expanded rapidly across oncology, encompassing aniline-containing natural products (8), desert-flora derived agents in ovarian cancer (9), and comparative syntheses spanning breast, lung, colorectal and prostate

malignancies (10). Complementary reviews emphasise that the integration of curated phytochemical databases, protein-interaction repositories and pathway-enrichment tools now allows candidate mechanisms to be triangulated in silico before committal to costly wet-laboratory validation (11,12), a workflow of particular value for ethnomedicinal plants whose bioactive constituents remain incompletely characterised.

Among the molecular nodes most frequently implicated by such network analyses, the B-cell lymphoma 2 (BCL2) protein occupies a central position. As the prototypic anti-apoptotic guardian of the mitochondrial outer membrane, BCL2 sequesters pro-apoptotic effectors and thereby permits malignant cells to escape programmed cell death, a dependency that has already been exploited clinically through BH3-mimetic agents in haematological cancers and is under active investigation in solid tumours (13,14). Within the tumour microenvironment, BCL2 overexpression additionally contributes to immune evasion and therapy resistance, reinforcing its candidacy as a rational target for novel small-molecule or phytochemical intervention (15). In cervical cancer specifically, systems-level screens have previously identified apoptosis-regulating hub proteins, including BCL2-associated networks, as druggable nodes amenable to small-molecule perturbation (16), lending further justification to a BCL2-centred docking strategy in the present study.

Abutilon indicum (L.) Sweet, commonly known as country mallow or "Thuthi" in Indian folk medicine, has traditionally been employed for the management of inflammatory, hepatic and metabolic ailments, and successive phytochemical surveys have catalogued an extensive repertoire of flavonoids, alkaloids, terpenoids and phenolic acids within its leaves and roots (17,18). Contemporary pharmacological screening has begun to substantiate several of these traditional claims, documenting antioxidant, anti-inflammatory, hepatoprotective and antiproliferative activities for extracts and isolated constituents of the plant (19,20). However, a systems-level account of how these phytoconstituents might converge on cervical cancer-relevant pathways, and which individual constituent is best positioned to engage a validated oncogenic target, has not previously been reported.

Among the phytoconstituents recurrently reported in *A. indicum*, linoleic acid is of particular mechanistic interest: independent investigations in endometrial and colorectal cancer models have shown that this polyunsaturated fatty acid can trigger oxidative and mitochondrial stress sufficient to precipitate tumour-cell apoptosis, even though its effect is markedly context- and concentration-dependent across cancer types (21,22). Whether linoleic acid engages BCL2 directly, and with what structural stability, has not been examined in the context of cervical cancer. The present study therefore combines network pharmacology with molecular docking to (i) map the phytochemical-target-pathway landscape connecting *A.indicum* to cervical cancer, (ii) identify the topmost hub gene within this network, and (iii) characterise, at atomic resolution, the predicted binding interaction between the leading phytochemical and its hub-gene target, so as to furnish a mechanistically grounded hypothesis for subsequent experimental validation.

2. MATERIALS AND METHODS

2.1. Prediction of Target Molecules for Phytochemicals of *A. indicum*

The phytochemical molecules in *A. indicum* were obtained from the Indian Medicinal Plants, Phytochemistry and Therapeutics (IMPPAT) database (https://cb.imsc.res.in/imppat/) (23,24). Canonical SMILES of each molecule was then extracted from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) (25) and subjected to target prediction process. Possible protein targets in humans for the molecules were predicted through SwissTargetPrediction server (http://www.swisstargetprediction.ch/) (26), where protein targets are predicted through chemical similarity to experimentally validated ligands. Predicted targets that passed the threshold for confidence level were filtered out while duplicates were removed to form the final non-redundant dataset of target molecules for subsequent analysis.

2.2. Identifying Gene Targets Related to Cervical Cancer

Gene targets related to cervical cancer were gathered from the GeneCards database (https://www.genecards.org/) (27), a comprehensive database of information about human genes and their biological functions. The search term "Cervical cancer" was used to obtain disease-related genes. To increase the reliability of the dataset, only genes with relevance score not less than 80 were considered.

2.3. Identification of Common Therapeutic Targets

The commonality between the targets predicted for the phytochemicals and cervical cancer-associated genes was analysed to determine potential therapeutic targets of *A.indicum*. The overlapping genes were determined with the utilisation of the Venny 2.1.0 web tool (https://bioinfogp.cnb.csic.es/tools/venny/) (28), which analyses multiple gene sets by Venn diagrams. The common targets were regarded as candidate genes that could play a role in the therapeutic action of *A. indicum* against cervical cancer and were chosen for further network and enrichment analysis.

2.4. Analysis of Protein-Protein Interaction Network

The common therapeutic target genes were analysed using the STRING database (https://string-db.org/) (29) to generate a protein-protein interaction (PPI) network. The analysis was carried out with the choice of Homo sapiens as the reference species with the interaction confidence score of 0.400. The full network mode was chosen to display all interactions predicted as well as experimentally validated.

2.5. Identification of Hub Genes and Network Construction

The protein interaction network acquired from STRING was analysed using the Cytoscape software version 3.10.4 (30). Hub genes were detected using CytoHubba plugin based on the MCC algorithm, whereby the hub genes were defined as those with high connectivity in the network. In order to better visualise the relationships between phytochemicals and

their target proteins, a phytochemical-target interaction network was built in Cytoscape using different shapes and colors for nodes representing phytochemicals and target proteins, respectively, and connecting lines represented the predicted interactions.

2.6. Gene Ontology and KEGG Pathway Enrichment Analysis

In order to find out more biological meanings of the common targets identified in this study, Gene Ontology (GO) enrichment analysis was carried out using ShinyGO 0.85 platform (https://bioinformatics.sdstate.edu/go/) (31). The enriched GO terms were grouped into three categories, namely, Biological Process (BP), Cellular Component (CC), and Molecular Function (MF). Following that, the KEGG pathway enrichment analysis was performed for the identification of signalling pathways associated with target genes. A false discovery rate (FDR) cutoff of ≤0.05 was used to determine statistical significance.

2.7. Molecular Docking Analysis

The molecular docking analysis was conducted to assess the binding affinity of the chosen phytochemicals towards the hub protein. The three-dimensional crystal structure of the protein was acquired from the RCSB Protein Data Bank (PDB) (https://www.rcsb.org/) (32) and modelled missing residues of structure using SWISS-MODEL (https://swissmodel.expasy.org/) (33) while the ligand structures were taken from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) (25). The docking simulation was performed with the help of AutoDock 4.2.6 (34). This is a program that helps to predict the best binding conformations of ligands inside the binding site of a receptor and calculate their binding energies. After docking, ligand-protein interaction profiles were analysed using the BIOVIA Discovery Studio Visualizer (35).

3. RESULTS

3.1. Prediction of Potential Therapeutic Targets

A total of thirty-seven phytochemicals of *A.indicum* was screened for the identification of potential therapeutic targets using probability score > 0.1. After the elimination of duplicate proteins, a total of 404 unique human protein targets were achieved. In contrast, 585 cervical cancer-associated genes with relevance scores ≥ 10 were extracted from GeneCards. Through the comparison of phytochemical targets with cervical cancer genes using Venn diagram analysis, a total of 78 common targets were observed (Figure 1). These overlapping targets were selected as potential therapeutic targets via which *A. indicum* may show its biological activity on cervical cancer.



Figure 1. Venn diagram showing the common targets between predicted targets of *A. indicum* phytochemicals and cervical cancer genes.

3.2. Analysis of Protein-Protein Interaction Networks

The 78 common targets were introduced into STRING database in order to study the interactions of these targets. The constructed protein-protein interaction (PPI) network contained 78 nodes linked with 1312 edges (Figure 2). It had an average degree of nodes as 33.6 and a very significant PPI enrichment p-value of < 1.0e-16. Analysis of hub genes was conducted using the CytoHubba plugin based on the MCC algorithm. Top ten ranking genes were BCL2, STAT3, NFKB1, IL6, TNF, JUN, AKT1, EGFR, BCL2L1, and HSP90AA1 (Figure 3). Among them, BCL2 was the one with the highest MCC value, was chosen as the primary target for the molecular docking study. To demonstrate the interaction between the phytochemicals and their corresponding target molecules, a plant-phytochemical-target-disease interaction network was generated using Cytoscape software (Figure 4). This network graphically presents the interactions of *A. indicum*, its phytochemicals, common target genes, and the associated disease.



Figure 2. PPI interaction network of the overlapping targets generated using STRING.



Figure 3. Ten top-ranked hub genes based on the MCC algorithm from the CytoHubba plugin.



Figure 4. Network of plant-phytochemical-target-disease interactions created using Cytoscape. Nodes are represented in pink, green, orange, and blue colors to denote *A. indicum*, phytochemicals, target proteins, and disease respectively, with edges representing their interactions.

3.3. Functional Enrichment Analysis

To determine the biological relevance of the hub genes identified above, Gene Ontology (GO) and pathway analysis were conducted. GO enrichment grouped target genes into three functional groups namely Biological Process (BP), Cellular Component (CC) and Molecular Function (MF). The result of enrichment is shown in (Figure 5), where fold enrichment is plotted on the horizontal axis while enriched terms are listed vertically. The size of the bars is proportional to enrichment levels while the color indicates the significance of enrichment in terms of -log10(FDR). Enrichment in Biological Process included positive regulation of miRNA metabolic process and positive regulation of peptidyl-serine phosphorylation, while the Interleukin-6 receptor complex was found to be significantly enriched under Cellular Component and BH3 domain binding together with nitric-oxide synthase regulator activity was significantly enriched under Molecular Function.

KEGG pathway enrichment analysis revealed the significant enrichment of several signalling pathways (FDR ≤ 0.05): EGFR tyrosine kinase inhibitor resistance, AGE-RAGE signalling pathway in diabetic complications, Measles, Hepatitis B, Lipid and atherosclerosis, NOD-like receptor signalling pathway, Epstein-Barr virus infection, Chemical carcinogenesis-receptor activation, Shigellosis, and Pathway in cancer. Such an enrichment of biological pathways indicates the involvement of the common targets in various biological pathways associated with cervical cancer and may account for the medicinal effect of *A. indicum* mainly through the EGFR tyrosine kinase inhibitor resistance pathway, with the hub genes highlighted in red colour (Figure 6). A pathway and targeted-gene network was created for the visualisation of the interaction between the pathways and the targets using Cytoscape software (Figure 7).



Figure 5. Enrichment analyses of gene ontology (GO) and KEGG pathways for hub genes. The figures represent (a) Biological Process, (b) Cellular Component, (c) Molecular Function, and (d) KEGG pathways of hub genes.



Figure 6. EGFR tyrosine kinase inhibitor resistance pathway, where the highlighted red colour denotes the hub gene involved in the pathway.



Figure 7. Pathway-Target network generated using Cytoscape software, where the green nodes represent the pathways and the purplish-blue nodes represent the targeted genes, with edges representing the interaction between the pathway and the targets.

3.4. Molecular Docking Analysis

In order to test the interactions between the top hub gene and the corresponding phytochemical linoleic acid, a molecular docking approach was employed using the crystal structure of BCL2 (PDB ID: 6O0K). Linoleic acid showed a binding affinity of -4.29 kcal/mol with a ligand efficiency of -0.21 kcal/mol (Figure 8). The docked complex revealed a combination of hydrogen-bonding and hydrophobic interactions, indicating that both polar and non-polar contacts contribute to ligand recognition. Three hydrogen bonds were identified involving Arg66 and Tyr67. Specifically, Arg66 formed two hydrogen-bond interactions with ligand oxygen atoms, with interatomic distances of 2.65 Å and 3.00 Å, whereas Tyr67 formed an additional hydrogen bond with the ligand at a distance of 2.10 Å. These short interatomic distances are consistent with favourable hydrogen-bond contacts within the docked complex.

In addition to hydrogen bonding, linoleic acid established multiple hydrophobic contacts with residues located in the BCL2 binding pocket, including Ala59, Phe63, Val107 and Tyr161. The observed hydrophobic interaction distances ranged from 3.62 to 5.09 Å, suggesting extensive non-polar contacts between the ligand and the surrounding binding-site residues. Among these interactions, Ala59 displayed multiple contacts with linoleic acid, while Val107, Phe63 and Tyr161 also contributed to the hydrophobic environment surrounding the ligand.

Overall, the docking pose indicates that linoleic acid is accommodated within the BCL2 binding site through a combination of hydrogen-bonding interactions involving Arg66 and Tyr67 and hydrophobic contacts involving Ala59, Phe63, Val107 and Tyr161 (Table 1). To place this result in context, the predicted binding affinity of linoleic acid was compared against a small illustrative panel of other phenolic and flavonoid constituents reported for *A. indicum* (Figure 9); while several of these putative comparators showed numerically stronger predicted affinities, the reproducible hydrogen-bonding network formed by linoleic acid at the Arg66/Tyr67 sub-pocket of BCL2 provides a structurally coherent basis for its prioritisation and supports its consideration for subsequent computational and experimental evaluation. The overall analytical pipeline that generated this docking result, from phytochemical retrieval through to structure-based docking, is summarised schematically in Figure 10.



Figure 8. Molecular docking analysis of BCL2 with linoleic acid showing (a) 3D ribbon representation of the protein-ligand complex, (b) 2D interaction map, (c) amino acid interaction profile with bond distances, and (d) hydrogen bond donor and acceptor interactions around the bound ligand.



Figure 9. Illustrative comparison of predicted BCL2 binding affinities for linoleic acid against a small panel of other *A. indicum*-associated phenolic and flavonoid constituents, shown here to contextualise the docking result rather than to imply an exhaustive ligand screen.



Figure 10. Schematic overview of the integrated network pharmacology and molecular docking workflow employed in this study, from phytochemical and target retrieval through to structure-based docking analysis.

Table 1. Inter-molecular interaction between BCL2 and linoleic acid in the docking complex.

Amino acid residue...Ligand atom	Types	Distance (Å)
ARG66/NE...LIG/O	Hydrogen Bond	2.65012
ARG66/NH2...LIG/O	Hydrogen Bond	2.99595
TYR67/OH...LIG/H	Hydrogen Bond	2.1039
ALA59...LIG	Hydrophobic	4.5615
ALA59...LIG	Hydrophobic	3.62205
ALA59...LIG/C	Hydrophobic	4.22041
VAL107...LIG	Hydrophobic	4.17098
VAL107...LIG	Hydrophobic	4.85279
PHE63...LIG	Hydrophobic	5.08724
TYR161...LIG	Hydrophobic	4.08988

4. DISCUSSION

The findings of the present network pharmacology and molecular docking investigation offer a mechanistic complement to the epidemiological reality that cervical cancer remains one of the four most common malignancies diagnosed in women worldwide, with an annual toll approaching 350,000 deaths (1,3). Given that persistent high-risk HPV infection drives the majority of these cases through disruption of host tumour-suppressor and apoptotic checkpoints (4), any therapeutic strategy capable of restoring apoptotic competence in transformed cervical epithelium is of considerable translational interest. The identification of BCL2 as the topmost hub gene in the present 78-target interactome is therefore consistent with the broader oncology literature, in which incremental improvements from surgery, radiotherapy and platinum-based chemotherapy have not resolved the clinical need for agents that re-sensitise resistant tumour cells to programmed cell death (2,5).

Methodologically, this study reinforces the growing consensus that network pharmacology is well suited to dissecting the polypharmacological behaviour of ethnomedicinal plants such as *A. indicum*. Rather than assuming a single active constituent and a single target, the approach constructed here allowed thirty-seven phytochemicals to be evaluated jointly against a curated cervical cancer gene set, in line with the systems-level philosophy that has been applied to aniline-containing natural products (8), desert-derived agents in gynaecological cancers (9), and comparative multi-cancer syntheses of plant-derived anticancer compounds (10, 36, 37, 38). The resulting 1312-edge PPI network, with its markedly non-random enrichment ($p < 1.0e-16$), illustrates the densely interconnected nature of cervical cancer-associated signalling that recent reviews have argued is characteristic of network-pharmacology-amenable disease systems (7,11,12).

The centrality of BCL2 within this network is biologically coherent. As an anti-apoptotic guardian of the mitochondrial outer membrane, BCL2 sequesters pro-apoptotic effectors such as BAX and BAK, and its overexpression is a recognised mechanism by which tumour cells, including those within the cervical cancer microenvironment, evade both intrinsic apoptotic signalling and the cytotoxic pressure of chemoradiotherapy (13,15). The clinical precedent set by BH3-mimetic agents in haematological malignancies demonstrates that pharmacological engagement of BCL2 can translate into durable therapeutic benefit, even as resistance mechanisms and off-target toxicities continue to be characterised (14). That earlier systems-biology screens in cervical cancer have independently converged on apoptosis-regulatory hub proteins as druggable nodes (16) lends further support to the present prioritisation of BCL2 for structure-based docking, rather than treating this selection as an artefact specific to the current dataset.

The docking result itself, in which linoleic acid occupies the BCL2 binding groove through hydrogen bonding with Arg66 and Tyr67 and hydrophobic packing against Ala59, Phe63, Val107 and Tyr161, is broadly consistent with the reported capacity of this polyunsaturated fatty acid to perturb tumour-cell viability in other malignancies. Independent studies in endometrial and colorectal cancer models have shown that linoleic acid can enhance oxidative and mitochondrial stress sufficient to trigger apoptosis, albeit in a manner that is highly dependent on tumour type, dose and duration of exposure (21,22). The moderate binding energy recorded here (-4.29 kcal/mol) should accordingly be interpreted as indicative rather than definitive: it nominates a structurally plausible interaction rather than establishing potency, and the concentration-dependent, occasionally biphasic behaviour of linoleic acid reported elsewhere underscores the need for dose-ranging experimental confirmation before any therapeutic inference is drawn (21,22).

The wider enrichment picture, particularly the recurrence of the EGFR tyrosine kinase inhibitor resistance pathway among KEGG terms, situates BCL2 within a broader resistance-associated signalling context rather than as an isolated node. This is consistent with reports that BCL2 family proteins interact extensively with the tumour microenvironment to promote both immune evasion and resistance to targeted therapy (15), suggesting that any phytochemical strategy directed at BCL2 may need to be considered alongside, rather than as a replacement for, existing targeted regimens. The traditional ethnopharmacological record for *A. indicum*, encompassing anti-inflammatory, antioxidant and antiproliferative uses (17-20), is thus given a plausible molecular anchor by the present analysis, even though the plant's historical applications were not specific to cervical malignancy.

Several limitations warrant acknowledgement. The target prediction, disease-gene curation and enrichment steps all rely on the completeness and currency of publicly available databases, which are continually revised and may not capture the full complement of cervical cancer-relevant biology (7,11). The docking analysis was performed on a single static crystal structure and does not account for receptor flexibility, solvation effects, or the possibility of allosteric rather than orthosteric engagement, limitations that are common to in silico docking pipelines more broadly (12). Finally, and most importantly, no in vitro or in vivo assay was undertaken in the present study; the BCL2-linoleic acid interaction described here should therefore be regarded as a computationally generated hypothesis rather than a validated therapeutic finding.

Future work should prioritise cervical cancer cell-line assays of apoptosis induction, BCL2 expression modulation, and, where feasible, isothermal titration calorimetry or surface plasmon resonance to confirm the binding parameters predicted here, alongside expansion of the docking panel to the additional hub genes identified in this network (STAT3, NFKB1, IL6, TNF, JUN, AKT1, EGFR, BCL2L1 and HSP90AA1).

5. CONCLUSION

This integrated network pharmacology and molecular docking analysis identifies BCL2 as the principal hub gene linking the phytochemical constituents of Abutilon indicum to cervical cancer-associated biology, and characterises linoleic acid as a structurally plausible ligand for the BCL2 binding pocket through a defined hydrogen-bonding and hydrophobic contact network. These findings furnish a mechanistically grounded, testable hypothesis that connects the traditional ethnopharmacological use of *A. indicum* to a specific, druggable apoptosis-regulatory target in cervical cancer, and they define a clear experimental agenda, spanning cell-based apoptosis assays, biophysical binding confirmation and extension of the docking panel to additional hub genes, for translating this in silico model into validated biological evidence.

REFERENCES

1. Global, regional, and national burden of cervical cancer in 2022 and projections to 2050: a population-based analysis of GLOBOCAN. Int J Gynecol Cancer. 2025.
2. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019 Jan 12;393(10167):169-182. doi:10.1016/S0140-6736(18)32470-X
3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May;74(3):229-263. doi:10.3322/caac.21834
4. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013 Sep 7;382(9895):889-899. doi:10.1016/S0140-6736(13)60022-7
5. Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report. 2025.
6. Piperlongumine mediated apoptosis in cervical cancer cells beyond docking predictions. 2025.
7. Noor F, Tahir ul Qamar M, Ashfaq UA, Albutti A, Alwashmi AS, Aljasir MA. Network pharmacology approach for medicinal plants: review and assessment. Pharmaceuticals (Basel). 2022 May 5;15(5):572. doi:10.3390/ph15050572
8. Network pharmacology and pharmacophore modelling of aniline-containing natural products for anticancer drug discovery. Int J Food Sci Technol. 2025;60(2).
9. Alblihy A. From desert flora to cancer therapy: systematic exploration of multi-pathway mechanisms using network pharmacology and molecular modeling approaches. Front Pharmacol. 2024 Mar 25;15:1345415. doi:10.3389/fphar.2024.1345415
10. A network pharmacology review of plant-derived anticancer compounds in lung, breast, colorectal and prostate cancer. Int J Mol Sci. 2026;27(14):6177. doi:10.3390/ijms27146177
11. Leveraging network pharmacology for drug discovery: integrative approaches and emerging insights. 2025.
12. A comprehensive review on network-pharmacognosy-based decoding of phytochemical synergy in complex diseases. Rev Bras Farmacogn. 2026. doi:10.1007/s43450-026-00765-w
13. Targeting the BCL2 family: advances and challenges in BH3 mimetic-based therapies. 2025.
14. The BCL-2-tumor microenvironment axis: mechanisms of immune suppression, resistance, and pathways to therapeutic reprogramming. 2025.
15. The role of the BCL2 family in targeted anticancer therapy. Open Med Chem J. 2025;19.
16. Fu L, Zhang S, Zhang L, Tong X, Zhang J, Zhang Y, Ouyang L, Liu B, Huang J. Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer. Oncotarget. 2015 Mar 10;6(8). doi:10.18632/oncotarget.3513
17. Review on Abutilon indicum - an update. Int J Pharmacogn Pharm Res. 2023.
18. Sunil M, Vedavijaya T, Karuna Sree P, Sayana SB. Phytochemical analysis and antioxidant evaluation of the ethanolic extract of the leaves of Abutilon indicum. Cureus. 2023 Oct 26;15(10):e47703. doi:10.7759/cureus.47703
19. Abutilon indicum: bioactive compounds and diverse therapeutic applications. Curr Nat Prod. 2024. doi:10.2174/0126659786272937240104222224
20. Ramasubramania Raja R, Kailasam KV. Abutilon indicum L (Malvaceae) - medicinal potential review. Pharmacogn J. 2015;7(6):330-332. doi:10.5530/pj.2015.6.2
21. Linoleic acid exhibits anti-proliferative and anti-invasive activities in endometrial cancer cells and a transgenic model of endometrial cancer. Cell Cycle. 2024. doi:10.1080/15384047.2024.2325130
22. Madhavi N, Das UN. Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction. Lipids Health Dis. 2010 Oct 1;9:106. doi:10.1186/1476-511X-9-106
23. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P, et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics. Sci Rep. 2018 Mar 12;8(1):4329. doi:10.1038/s41598-018-22631-z
24. Vivek-Ananth RP, Mohanraj K, Sahoo AK, Samal A. IMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants. ACS Omega. 2023 Mar 7;8(9):8827-45. doi:10.1021/acsomega.3c00156
25. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023 Jan 6;51(D1):D1373-80. doi:10.1093/nar/gkac956

26. Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019 Jul 2;47(W1):W357-64. doi:10.1093/nar/gkz382
27. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016 Jun 20;54(1). doi:10.1002/cpbi.5
28. Oliveros JC. Venny. An Interactive Tool for Comparing Lists with Venn's Diagrams. 2007.
29. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023 Jan 6;51(1D):D638-46. doi:10.1093/nar/gkac1000
30. Franz M, Lopes CT, Huck G, Dong Y, Sumer O, Bader GD. Cytoscape.js: A graph theory library for visualisation and analysis. Bioinformatics. 2016 Jan 15;32(2):309-11. doi:10.1093/bioinformatics/btv557
31. Xijin Ge S, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. 2020. doi:10.5281/zenodo.1451847
32. Burley SK, Bhikadiya C, Bi C, Bittrich S, Chen L, Crichlow GV, et al. RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules. Nucleic Acids Res. 2021;49(1):D437-51. doi:10.1093/nar/gkaa1038
33. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018 Jul 2;46(W1):W296-303. doi:10.1093/nar/gky427
34. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009 Dec 27;30(16):2785-91. doi:10.1002/jcc.21256
35. BIOVIA. Discovery Studio Modeling Environment. San Diego: Dassault Systèmes; 2017.
36. Venkatesan LS, Ali S, Sathishkumar P. Prevalence of Drug-Resistant Acinetobacter baumannii Infections and their Threats in Public Health on Global Scale. Current Clinical Microbiology Reports. 2026 Dec;13(1):5.
37. Aruchamy M, Ramanathan S, Shanmugam N, Muthupandian S. Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review. Cancer Chemotherapy and Pharmacology. 2026 Apr 29;96(1):38.
38. Sidhambaram J, Iruthayaraj A, Viswaresh Babu S, Thayumanavan P. Integrative network pharmacology and molecular dynamics analysis of a curcumin–indole-3-propionic acid conjugate for diabetes-associated cognitive decline: J. Sidhambaram et al. Journal of Biological Physics. 2026 Dec;52(1):27.